Cancer Research Horizons launches the Cancer Impact Club to raise £5m

  • Club brings together a community of visionary philanthropists to boost investment into high-potential, early-stage cancer ventures 
  • Launch event will take place on Thursday 20 March in London 
  • 20 March 2025

Cancer Research Horizons, the innovation arm of Cancer Research UK, launches the Cancer Impact Club, a community of business builders whose philanthropy, expertise and networks will help shape the future of cancer treatment. The club has recruited 13 members already, raising £1.3m of its £5m target.

Advances in biomedical understanding, technology and machine learning have brought us to the threshold of a golden age of scientific discovery. However, far too many potentially breakthrough innovations are lost in the funding gap between cutting-edge academic cancer research and a start-up becoming ready for commercial investment. The Cancer Research Horizons Seed Fund was launched in June 2022 to tackle this challenge, with a £15m commitment from Cancer Research UK. Managed by Cancer Research Horizons’ Ventures team, the Seed Fund accelerates early-stage treatments, devices and solutions into patient impact through funding, business building support and expert advice.

The Cancer Impact Club aims to bring together a maximum of 50 members – comprising entrepreneurs and leaders from private equity, venture capital, and associated companies – by the end of 2025 to raise £5m, to help double the Seed Fund’s impact. Members commit to a donation of £100,000 over three years, with every £1 donated matched by £1 from the Seed Fund to be invested in high-potential cancer ventures.

Early members of the club include founding member Darren Redmayne (former CEO of Cardano and a senior volunteer at Cancer Research UK), Richard Anthony (CEO of Evercore Private Funds), Dale Lattanzio (Managing Partner at DRC Savills), Robert Easton (former partner at Carlyle, now an advisor at Melior Equity Partners), Katherine Priestley (Founder and Managing Director of Park Vale Capital), Alison Howe (former Founder and Managing Director, Strategic Consultants International), and Christiian Marriott (former Head of Investor Relations at Equistone Partners). There are currently 13 Cancer Impact Club members in total. Cancer Research Horizons aims to close with its target 50 members by October 2025.

“The launch of the Cancer Impact Club marks a significant step forward in our mission to bridge the funding gap that too often stalls early-stage breakthroughs. By uniting visionary philanthropists, entrepreneurs, and business leaders, the Club will amplify the impact of our Seed Fund, ensuring that high-potential cancer ventures have the resources and expertise needed to transform cancer treatment,” said Iain Foulkes, CEO of Cancer Research Horizons and Executive Director of Research and Innovation, Cancer Research UK. “Together, we can accelerate the journey from scientific discovery to life-saving solutions, changing the future for those affected by cancer.”

Together with a recent £10m donation from Garfield Weston Foundation, the launch of the Cancer Impact Club brings Cancer Research Horizons closer to its £30m target for the Seed Fund.

Darren Redmayne, a senior volunteer for Cancer Research UK, who was key to developing the Cancer Impact Club proposal, said, "Joining the Cancer Impact Club is an exciting opportunity to support turning scientific breakthroughs into tests, treatments and devices that will benefit patients. By collaborating with a like-minded community of entrepreneurial individuals and leveraging our collective expertise, we can help bring transformative ideas to life. If the ground-breaking ventures the Seed Fund backs succeed, they will deliver treatments that don't currently exist to cancer patients, and that could have a game-changing impact on countless lives."

Learn more about the Cancer Impact Club here: https://www.cancerresearchhorizons.com/investors/donating-cancer-impact-booster/cancer-impact-club

ENDS

About Cancer Research Horizons

Cancer Research Horizons is the innovation engine of Cancer Research UK – the world's largest charitable funder of cancer research. It brings together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. It focuses on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients. 

To date, it has played an instrumental role in forming over 70 start-ups. It has helped bring 14 cancer drugs to market, borne out of Cancer Research UK's pioneering research. Through these drugs, it has enabled in excess of 6 million courses of treatment for cancer patients across the world. 

With access to Cancer Research UK's network of 4,000 exceptional researchers, and £400m of annual research spend, it is a powerful partner in the fight to conquer cancer. By uniting its commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, data licensing and collaboration, spin-out creation, and offer a full spectrum of drug discovery and clinical capabilities.  

Every penny it makes goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered.  

For more information and to get in touch with the team, visit cancerresearchhorizons.com

Contact

Tanya Hughes 
Investor and External Relations Lead, Ventures 
Cancer Research Horizons 
E: [email protected]